e-therapeutics plc
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. The company offers HepNet, a hepatocyte-focused computational platform that enables identification of novel gene targets, improves drug design, and automated evaluation; and GalOmic, a proprietary siRNA chemistry that generates potent and long-acting RNAi medicines. Its preclinical products are ETX-312 to trea… Read more
e-therapeutics plc (ETXPF) - Total Assets
Latest total assets as of July 2024: $46.68 Million USD
Based on the latest financial reports, e-therapeutics plc (ETXPF) holds total assets worth $46.68 Million USD as of July 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
e-therapeutics plc - Total Assets Trend (2007–2024)
This chart illustrates how e-therapeutics plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
e-therapeutics plc - Asset Composition Analysis
Current Asset Composition (January 2024)
e-therapeutics plc's total assets of $46.68 Million consist of 94.4% current assets and 5.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 82.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $407.00K | 1.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how e-therapeutics plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: e-therapeutics plc's current assets represent 94.4% of total assets in 2024, an increase from 69.4% in 2007.
- Cash Position: Cash and equivalents constituted 82.8% of total assets in 2024, up from 35.6% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 12.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 1.6% of total assets.
e-therapeutics plc Competitors by Total Assets
Key competitors of e-therapeutics plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
e-therapeutics plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - e-therapeutics plc generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - e-therapeutics plc is currently not profitable relative to its asset base.
e-therapeutics plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 23.41 | 22.20 | 15.57 |
| Quick Ratio | 23.41 | 17.30 | 15.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $43.00 Million | $ 34.73 Million | $ 6.55 Million |
e-therapeutics plc - Advanced Valuation Insights
This section examines the relationship between e-therapeutics plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.15 |
| Latest Market Cap to Assets Ratio | 2.30 |
| Asset Growth Rate (YoY) | -27.9% |
| Total Assets | $24.97 Million |
| Market Capitalization | $57.33 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values e-therapeutics plc's assets at a significant premium ( 2.30x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: e-therapeutics plc's assets decreased by 27.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for e-therapeutics plc (2007–2024)
The table below shows the annual total assets of e-therapeutics plc from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-01-31 | $24.97 Million | -27.92% |
| 2023-01-31 | $34.64 Million | -12.72% |
| 2022-01-31 | $39.69 Million | +101.96% |
| 2021-01-31 | $19.65 Million | +211.49% |
| 2020-01-31 | $6.31 Million | -36.13% |
| 2019-01-31 | $9.88 Million | -40.94% |
| 2018-01-31 | $16.73 Million | -25.86% |
| 2017-01-31 | $22.56 Million | -46.25% |
| 2016-01-31 | $41.97 Million | +9.99% |
| 2015-01-31 | $38.16 Million | -16.36% |
| 2014-01-31 | $45.62 Million | +297.81% |
| 2013-01-31 | $11.47 Million | -24.89% |
| 2012-01-31 | $15.27 Million | +820.31% |
| 2011-01-31 | $1.66 Million | -55.38% |
| 2010-01-31 | $3.72 Million | +199.36% |
| 2009-01-31 | $1.24 Million | -54.30% |
| 2008-01-31 | $2.72 Million | +544.08% |
| 2007-01-31 | $422.00K | -- |